Better business coming in than going out: management describes the quality of new intake visibly exceeding what it is re
The model's full reasoning — Q3 2018 call → NOWe need to determine if management conveys that the business being taken in now is of visibly higher quality than the business it is finishing, replacing, or letting run off. The key is a contrast between incoming and outgoing business, with the incoming being better, and that this turnover is real and current, with results improving as the old rolls off. Looking at the transcript, there are several mentions of new developments, but we need to see if there's a specific contrast between new and old business quality. For example, the launch of TIBSOVO is new, but is it contrasted with IDHIFA? They mention that TIBSOVO is new, but they don't say it's better quality than IDHIFA in terms of economics. They talk about testing rates and awareness, but not about the quality of the business. There's also the sNDA for newly diagnosed AML, which is a new indication, but again, not a contrast between incoming and outgoing business. The question is about whether management conveys that the business they are taking in now is of higher quality than the business they are finishing or replacing. This could be about new contracts, new products, new customers, etc. In the transcript, there is no explicit statement that the new business is better than the old. They discuss progress, but not a contrast in quality. For example, they talk about the launch of TIBSOVO, but they don't say that TIBSOVO business is better than IDHIFA business. They talk about the AGILE trial, but that's a clinical trial, not a business intake. The only possible thing is the mention of the sNDA for newly diagnosed AML, which might be a new market, but they don't contrast it with the existing relapsed/refractory market in terms of quality. Also, they talk about the real-time oncology review, but that's about regulatory process. There is no mention of "incoming business" vs "outgoing business" in terms of economics, margins, duration, etc. Thus, the answer is NO. We need to be careful: the question asks if management conveys that the business being taken in now is of visibly higher quality than the business it is finishing, replacing, or letting run off. There is no such contrast in the transcript. They talk about growth, but not about a quality differential between new and old. Therefore, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| BBD | Banco Bradesco S.A. | Q3 2022 | 2022-11-09 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
HSTM · Q3 2017 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting incoming business against outgoing: - Patient Experience: "Existing clients also continue to convert from a phone modality to email and SMS text surveying modality... This conversion trend to continue... expected to have a positive impact... on patient experience margins." (lower price, higher margin shift already happening) - Provider Solutions: "the move from installed software sales to software as service sales... challenge revenue growth... but not profitability growth" and "backlog of unimplemented customers... significantly reduced" - Laerdal/HeartCode: "the new product we believe is right now based on contracts.
GFS · Q3 2021 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting the incoming business with the outgoing: compute revenue is declining "as expected" due to customers shifting to smaller nodes, while "newer high-margin customer designs" are ramping in 2H 2022 to offset it. They tie this directly to mix improvement from "d differentiated solutions become a larger portion" and "feature-rich" platforms (FDX, RF SOI, silicon photonics) growing while feature-rich CMOS is flat or down. LTAs signed now carry "pricing improvements" baked in for 2022+, with new agreements committing future capacity at those better terms.
CYBR · Q3 2021 → YESThe question is about whether management conveys that the new business they're taking in is of higher quality than the old business they're replacing, and that as the old rolls off, results will impro...YES Management explicitly contrasts the incoming subscription business (new logos, SaaS bookings, Privileged Cloud, EPM) as higher-quality than the outgoing perpetual license business it is replacing. They describe it as delivering “faster type of value,” “higher lifetime value over time,” and “more users and more products faster ,” while noting that the current revenue and profitability headwind from the mix shift is “obscuring the P&L” and that results will improve once the transition completes.